Exosome Isolation for Corneal Epithelial Stem Cell Growth
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for corneal epithelial diseases, such as corneal epithelial stem cell deficiency and diabetic keratopathy, are often ineffective or associated with risks like rejection and donor shortages, and there is a lack of therapeutic agents that effectively promote corneal epithelial stem cell growth and colony formation.
Innovation Solution
The use of mesenchymal stem cell-derived microparticles, specifically exosomes isolated by ultracentrifugation from the cell culture supernatant of human mesenchymal stem cells, which contain markers such as CD9, CD63, and CD81, and have a density of 1.13 g/mL to 1.19 g/mL, to promote the growth of corneal epithelial stem cells, maintain their undifferentiated state, or enhance colony formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (artificial lacrimal fluid, antibiotics, corneal transplant) are used for corneal epithelial diseases, then treatment coverage is provided, but effectiveness is limited and risks of rejection and donor shortage exist
Solution Approach 1:
The invention extracts and utilizes exosomes from mesenchymal stem cells, isolating the therapeutic components (growth factors, cytokines, miRNAs) from the source cells. This extraction approach provides the beneficial therapeutic effects while avoiding the limitations of whole-cell transplants, including rejection risks and donor shortages.
Solution Approach 2:
Exosomes serve as intermediary carriers that transfer bioactive molecules between cells. They mediate the therapeutic effect by delivering growth-promoting signals to corneal epithelial stem cells without requiring direct cell-to-cell contact or transplantation, thus avoiding immune rejection while maintaining therapeutic efficacy.
2Adaptability or versatility
If iPS cells are induced to differentiate into corneal epithelial cells, then potential therapeutic source is created, but clinical application is still in development and not yet available
Solution Approach 1:
The invention performs preliminary actions by characterizing and validating exosomes from mesenchymal stem cells with demonstrated therapeutic effects on corneal epithelial stem cells. This preliminary characterization provides a ready-to-apply therapeutic platform that can be immediately tested clinically, eliminating the lengthy differentiation and validation process required for iPS cell approaches.
3Manufacturing precision
If corneal epithelial stem cells are co-cultured with NIH/3T3 feeder cells to form colonies, then colony formation is achieved, but the method is complex and requires additional cell types
Solution Approach 1:
The invention extracts the essential colony-promoting factors from the complex NIH/3T3 feeder cell system and delivers them directly through purified exosomes. This extraction simplifies the culture system by removing the need for feeder cells while maintaining the colony formation capability through exosome-mediated delivery of growth factors and cytokines.
Solution Approach 2:
The invention creates a simplified copy of the feeder cell function by using exosomes that replicate the colony-promoting effects without requiring the actual feeder cells. The exosomes copy the essential signaling functions needed for colony formation, eliminating the complexity of maintaining feeder cell cultures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These mesenchymal stem cell-derived microparticles effectively promote the growth and colony formation of corneal epithelial stem cells, while maintaining their undifferentiated state, thereby providing protection to the corneal epithelium and offering a potential therapeutic solution for various corneal epithelial diseases.
Implementation Method 1
exosomes which are isolated by ultracentrifugation from the cell culture supernatant of human mesenchymal stem cells
Implementation Method 2
having a density as determined by density gradient centrifugation of 1.13 g/mL to 1.19 g/mL
Data Source
Figure 1
Figure 2~3
Figure 4
AI summary
The present invention relates to mesenchymal stem cell-derived microparticles having activity that promotes the growth of corneal epithelial stem cells and/or corneal epithelial cells, activity that maintains corneal epithelial stem cells in an undifferentiated state or promotes the formation of colonies thereby, and function that protects corneal epithelium.